Imatinib in the Treatment of Nephrogenic Systemic Fibrosis

American Journal of Kidney Diseases

Volumn 53, Issue 1, 2009, Pages 129-132

  Chandran, Sindhu ^a   Petersen, Jeffrey ^a   Jacobs, Charlotte ^a   Fiorentino, David ^a   Doeden, Katherine ^a   Lafayette, Richard A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

dialysis; gadolinium; Imatinib; systemic fibrosis

Indexed keywords

GADOLINIUM PENTETATE; IMATINIB;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; NEPHROGENIC SYSTEMIC FIBROSIS; SKIN BIOPSY; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RENAL DIALYSIS;

EID: 57649153080     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.08.029     Document Type: Article

References (19)

1. Galan A., Cowper S.E., and Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18 (2006) 614-617
2. Levine J.M., Taylor R.A., Elman L.B., et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30 (2004) 569-577
3. Daram S.R., Cortese C.M., and Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis 46 (2005) 754-759
4. Boyd A.S., Zic J.A., and Abraham J.L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 (2007) 27-30
5. Jimenez S.A., Artlett C.M., Sandorfi N., et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50 (2004) 2660-2666
6. Grobner T. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
7. Deo A., Fogel M., and Cowper S.E. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 (2007) 264-267
8. Broome D.R., Girguis M.S., Baron P.W., Cottrell A.C., Kjellin I., and Kirk G.A. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol 188 (2007) 586-592
9. Mendoza F.A., Artlett C.M., Sandorfi N., Latinis K., Piera-Velazquez S., and Jimenez S.A. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35 (2006) 238-249
10. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
11. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
12. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 358 (2001) 1421-1423
13. Beham-Schmid C., Apfelbeck U., Sill H., et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99 (2002) 381-393
14. Daniels C.E., Wilkes M.C., Edens M., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114 (2004) 1308-1316
15. Vuorinen K., Gao F., Oury T.D., Kinnula V.L., and Myllärniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 33 (2007) 357-373
16. Yoshiji H., Noguchi R., Kuriyama S., et al. Imatinib mesylate (STI571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 288 (2005) G907-G913
17. Wang S., Wilkes M.C., Leof E.B., and Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19 (2005) 1-11
18. Distler J.H., Jüngel A., Huber L.C., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56 (2007) 311-322
19. Kay J. Imatinib mesylate treatment improves skin changes of nephrogenic systemic fibrosis. Arthritis Rheum 56 (2007) S64-S65 (abstr)